



Biosimilar to Avastin[®]1

- Made in Spain¹
- Diluted solution storage of up to 12 hours vs 8 hours for Avastin^{1,2}
- Extended shelf life of up to 30 months vs 24 months for Avastin^{3,4}
- Covered by the Amneal PATHways[®] patient support program

Product Information

Unit of Sale	Unit of Sale Quantity	NDC	List (WAC) ⁵
100 mg/4 mL (25 mg/mL)	Pack of 1 Single-Dose Vial	70121-1754-01	\$718.60
400 mg/16 mL (25 mg/mL)	Pack of 1 Single-Dose Vial	70121-1755-01	\$2,874.40
HCPSC Code ⁶	Descriptor		
Q5126	Injection, bevacizumab-maly, biosimilar, (alysys), 10 mg		

IMPORTANT SAFETY INFORMATION

Indications and Usage

Alymsys (bevacizumab-maly) in the U.S. is a vascular endothelial growth factor inhibitor indicated for the treatment of:

- Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.
- Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.
- First-Line non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel.
- Recurrent glioblastoma in adults.
- Metastatic renal cell carcinoma in combination with interferon alfa.
- Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan.
- Epithelial ovarian, fallopian tube, or primary peritoneal cancer, in combination with paclitaxel.

Limitations of Use: Alymsys is not indicated for adjuvant treatment of colon cancer.

Please see next page for additional Important Safety Information and visit Alymsys.us for full Prescribing Information.

HCPSC, Healthcare Common Procedure Coding System; NDC, National Drug Code; WAC, wholesale acquisition cost.

Storage & Handling

Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton until time of use to protect from light. Do not freeze or shake the vial or carton.

Store diluted Alymsys solution at 2°C to 8°C (36°F to 46°F) for up to 12 hours.



1-866-4AMNEAL
(426-6325)

Amneal is pleased to offer reimbursement access and patient support services through the PATHways program.

PATHways Patient Access Specialists are available to assist healthcare providers and patients with:

- Benefit investigation
- Prior authorization support
- Affordability options like co-pay savings
- Claims assistance

Call toll-free Monday through Friday, 8 AM to 8 PM ET.

IMPORTANT SAFETY INFORMATION (continued)

Warnings and Precautions

Alymsys Important Safety Information includes warnings and precautions on severe and fatal hemorrhage; arterial and venous thromboembolic events; hypertension, hypertensive crisis, and hypertensive encephalopathy; renal injury, proteinuria, and nephrotic syndrome; posterior reversible encephalopathy syndrome; embryo-fetal toxicity; ovarian failure; congestive heart failure; gastrointestinal perforations and fistula; surgery and wound healing complications, and infusion-related reactions.

Adverse Reactions

Reported adverse drug reactions in patients include epistaxis, hemorrhage, hypertension, exfoliative dermatitis, proteinuria, back pain, headache, rhinitis, taste alteration, dry skin, and lacrimation disorder.

[Visit Alymsys.us](https://www.alymsys.us) for full Prescribing Information.

References: **1.** Alymsys. Prescribing information. Amneal Pharmaceuticals LLC; 2022. **2.** Avastin. Prescribing information. Genentech, Inc; 2022. **3.** Periodic Safety Update Report (PSUR) for Alymsys (bevacizumab-maly), April 22, 2022. **4.** Weiss KD. Biologics license application approval for bevacizumab. Food and Drug Administration; February 26, 2004. **5.** Wholesale acquisition cost (WAC) as of 12/31/2023. **6.** Centers for Medicare & Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) application summaries and coding recommendations; second quarter, 2024 HCPCS coding cycle.

Alymsys
(bevacizumab-maly)

